Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history

FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk

Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly

Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns

Novo Nordisk chief estimates industry reaching only 15% of potential customers at most

Danish pharma group seeks to broaden options and stay competitive with Eli Lilly

Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors